Prenetics Global Ltd reported that officer Brian J. Rosin, CFO of IM8 (US) LLC, beneficially owns 56,851 Restricted Stock Units (RSUs) under the company’s 2022 Share Incentive Plan. Each RSU represents a contingent right to receive one Class A Ordinary Share, par value $0.0015 per share. Of these, 18,950 RSUs vest on May 14, 2027, another 18,950 RSUs vest in four equal tranches on August 14, 2027, November 14, 2027, February 14, 2028 and May 14, 2028, and the remaining 18,951 RSUs vest in four equal tranches on August 14, 2028, November 14, 2028, February 14, 2029 and May 14, 2029, in each case subject to continued service. Upon vesting, the RSUs are settled and delivered in shares at an exercise price of $0.0000 per share.
Prenetics Global Ltd director Hudson Blake Leogrande acquired 2,000 Class A Ordinary Shares through the settlement of vested Restricted Stock Units. These RSUs were granted under the company’s 2022 Share Incentive Plan and each unit converts into one Class A Ordinary Share.
After the transaction, Leogrande directly holds 2,000 Class A Ordinary Shares, while 22,004 Restricted Stock Units remain outstanding. The vesting and settlement reflect routine equity compensation rather than open-market buying or selling.
Prenetics Global Limited filed an amended annual report to add audited 2025 financial statements for its equity‑method investee Insighta Holdings Limited, after determining Insighta was significant under SEC Regulation S‑X Rule 3‑09.
Insighta reported 2025 revenue of HK$573,247, up from HK$244,218 in 2024, mainly from diagnostics services and laboratory testing kits. Profit for the year rose to HK$5,804,192, helped by other income of HK$27,896,174, largely bank interest. As of December 31, 2025, Insighta held HK$561.2 million in bank deposits with more than three months to maturity and HK$61.0 million in cash and cash equivalents, against total liabilities of only HK$6.5 million. Total assets were HK$636.1 million and equity HK$629.6 million, with no income tax expense recorded for the year.
Prenetics Global Ltd director Cheng Yin Pan, through wholly owned entity M13 Capital Management Holdings Limited, exercised vested Restricted Stock Units into ordinary shares. On June 15, 2026, 15,873 RSUs converted into 15,873 Class A Ordinary Shares at a price of $0.0000 per share.
After the transaction, M13 Capital Management Holdings Limited held 59,051 Class A Ordinary Shares indirectly and 6,406 RSUs remained outstanding. This was a compensation-related RSU settlement rather than an open-market purchase or sale.
Prenetics Global Ltd director David Vanderveen exercised equity awards and received additional shares as part of his departure from the board. On June 15, 2026, 6,944 Class A Ordinary Shares were issued and delivered upon settlement of vested Restricted Stock Units granted under the company’s 2022 Share Incentive Plan.
Each RSU represents a right to receive one Class A Ordinary Share, and a derivative entry in the filing shows 8,681 RSUs tied to the same underlying shares. Any remaining unvested RSUs were forfeited in connection with Vanderveen’s termination of service as director. Following these settlements, he directly holds 45,249 Class A Ordinary Shares.
Prenetics Global Ltd director Leogrande Hudson Blake reported an initial holding of 24,004 Restricted Stock Units (RSUs). Each RSU represents a contingent right to receive one Class A Ordinary Share at an exercise price of $0.0000 per share. The 24,004 RSUs vested on June 4, 2026 and, subject to continued service, will be settled in shares through 12 equal monthly installments beginning July 4, 2026, with the full balance delivered by June 4, 2027.
Prenetics Global Limited reported strong growth for Q1 2026 while remaining loss-making. Revenue from continuing operations reached $36.0 million, with its IM8 nutrition brand contributing $33.8 million, up 23.1% from Q4 2025 and nearly six times Q1 2025 IM8 revenue.
Gross profit was $23.3 million, but loss from operations was $8.9 million and adjusted EBITDA showed a loss of $5.6 million. The total loss of $23.1 million was driven mainly by non‑cash items: an unrealized fair value loss on digital assets of about $9.8 million and an $8.0 million fair value loss on warrant liabilities.
IM8 momentum has accelerated into Q2 2026, with May monthly revenue of about $16.7 million, implying annualized recurring revenue of roughly $200 million. Management raised full‑year 2026 IM8 revenue guidance to $190–210 million and guided Q2 2026 revenue to $46–48 million, mostly from IM8. Prenetics also completed a full divestiture of digital assets for $41.3 million, held cash of $56.0 million as of March 31, 2026, and executed about $19 million of share repurchases under a $40 million program, while remaining debt‑free.
Prenetics Global Limited reports a board change and highlights rapid growth at its IM8 health brand. Director David Vanderveen resigned effective June 4, 2026, and the company appointed Hudson Leogrande, Founder and CEO of Comfrt, as an independent director. With his appointment, three of Prenetics’ four directors are independent under Nasdaq rules. IM8 has reached $100 million in annualized recurring revenue in 11 months and is projected to reach $250 million to $300 million ARR by the end of 2026. Prenetics recently raised its full-year 2026 IM8 revenue guidance to $190 million to $210 million and plans to apply Comfrt’s TikTok and Meta social commerce playbook to accelerate IM8’s expansion.
Cheng Yin Pan reported acquisition or exercise transactions in this Form 4 filing.
Prenetics Global Ltd director Cheng Yin Pan, through wholly owned entity M13 Capital Management Holdings Ltd, received a grant of 6,406 Restricted Stock Units under the company’s 2022 Share Incentive Plan. Each RSU represents the right to receive one Class A Ordinary Share.
The 6,406 RSUs are scheduled to vest on May 17, 2027, subject to continued service. After this grant, indirect holdings reported for this award total 22,279 RSUs. Vested RSUs are not automatically settled; delivery of Class A Ordinary Shares occurs at Cheng Yin Pan’s election in line with the company’s insider trading policy.
Prenetics Global Ltd director Cheng Yin Pan has amended insider disclosures to detail indirect holdings through M13 Capital Management Holdings Limited, a British Virgin Islands company wholly owned by him. M13 holds 43,178 Class A Ordinary Shares, 48,816 underlying warrant shares and 15,873 restricted stock units.
The warrants were originally issued in connection with Prenetics’ initial business combination completed on May 18, 2022 and, after a 1-for-15 reverse stock split on November 14, 2023, are exercisable for 48,816 Class A shares at an exercise price of $133.65 per 1.29 shares, or an effective $103.60 per share. The 15,873 RSUs vest on May 17, 2026 and each represents the right to receive one Class A share, with settlement timing elected by Cheng Yin Pan under the company’s insider trading policy.